Jefferies Group's IBRX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 300,000 shares of ImmunityBio, Inc. (IBRX) worth $2.3 M, representing 0.02% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Jefferies Group has maintained this position in IBRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 300,000 shares. Largest reduction occurred in Q2 2023, reducing 35,000 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's ImmunityBio (IBRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly ImmunityBio (IBRX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +300,000 | New Buy | 300,000 | $7.67 |
| Q3 2024 | -7,500 | Sold Out | 0 | $0.00 |
| Q2 2024 | +7,500 | New Buy | 7,500 | $6.32 |
| Q2 2023 | -35,000 | Sold Out | 0 | $0.00 |
| Q1 2023 | +35,000 | New Buy | 35,000 | $1.82 |
Jefferies Group's ImmunityBio Investment FAQs
Jefferies Group first purchased ImmunityBio, Inc. (IBRX) in Q1 2023, acquiring 35,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held ImmunityBio, Inc. (IBRX) for 5 quarters since Q1 2023.
Jefferies Group's largest addition to ImmunityBio, Inc. (IBRX) was in Q1 2026, adding 300,000 shares worth $2.3 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 300,000 shares of ImmunityBio, Inc. (IBRX), valued at approximately $2.3 M.
As of the Q1 2026 filing, ImmunityBio, Inc. (IBRX) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in ImmunityBio, Inc. (IBRX) was 300,000 shares, as reported at the end of Q1 2026.